Background/Aims: miR-146a has recently been shown to promote cell proliferation, migration, and invasion in many cancers, but the role of miR-146a in clear cell renal cell carcinoma (ccRCC) remains unclear. Methods: Reverse transcription quantitative PCR (RTqPCR) was performed to investigate the mRNA expression of miR-146a and CADM2 in ccRCC tissues. The luciferase reporter assay, Western blotting, and ChIP assay were carried out to explore the promoter and the transcription factor of miR-146a. Moreover, the effect of miR146a and CADM2 on ccRCC cells was explored using methyl thiazolyl tetrazolium, colony formation, and migration and invasion assays. The luciferase reporter assay, RT-qPCR, western blotting, and immunofluorescence assay were carried out to investigate whether CADM2 is directly regulated by miR-146a. A tumor xenograft model and immunohistochemical staining were used to examine the carcinogenic effect of miR-146a and CADM2 in vivo. Results: miR146a has been shown to promote cell proliferation, migration, and invasion. Here, we found that miR-146a is highly expressed in ccRCC tissues, whereas CADM2 is down-regulated. Hypoxia can induce the expression of miR-146a by stimulating its promoter. In addition, we demonstrated that miR-146a promoted and CADM2 inhibited proliferation, migration, and invasion of ccRCC cells. The 3' untranslated region (UTR) luciferase reporter assay identified that miR-146a targeted the 3' UTR of CADM2 and negatively regulated its expression. Ectopic expression of CADM2 counteracted the promoting effect of miR-146a on cell proliferation, migration, invasion, and the epithelial-mesenchymal transition process. Conclusion: Together, the finding of down-regulation of CADM2 by miR-146a can provide new insights into ccRCC pathogenesis and might contribute to the development of novel therapeutic strategies.
Introduction
Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, with an increasing disease incidence worldwide [1] . ccRCC is characterized by a deficiency of the von Hippel-Lindau (VHL) protein in almost 85% of sporadic cases [2, 3] . Most ccRCCs show VHL mutations and/or methylation silencing, which results in the enhancement of hypoxia-inducible factor (HIF) activity and hypoxia gene expression [4, 5] . Hypoxia can regulate tumorigenesis of ccRCC, and HIF-2α has been shown to repress tumor growth and angiogenesis of ccRCC [6, 7] . In addition, hypoxia could regulate gene expression by modulating mRNA stability and mRNA translation or by exerting an effect on transcriptional mechanisms and regulation mediated by microRNAs (miRNAs) [8] .
miRNAs are a class of small, noncoding RNA oligonucleotides that function as key regulators of gene expression by modulating complementary mRNAs, resulting in translational repression or mRNA degradation [9] . Increasing evidence has indicated that the development of different cancers is mediated by the dysregulation of miRNAs, which are considered to act as tumor suppressors or oncogenes [10, 11] . miRNAs also have a role in ccRCC development, regulating cell growth, migration, and invasion [12] [13] [14] [15] [16] . Several studies have shown the functions of miR-146a in cancers. For example, miR-146a promotes cell apoptosis by targeting transforming growth factor β-activated kinase 1 [17] , and facilitates colorectal cancer cell migration and invasion [18] . In addition, miR-146a has been shown to inhibit hepatocellular carcinoma by down-regulating TRAF6 expression [19] . In gastric cancer, miR-146a suppresses cell metastasis by targeting WASF2 [20] , and in breast cancer, it inhibits cell migration and invasion by targeting RhoA [21] . Together, these findings demonstrate that miR-146a acts as either a tumor suppressor or oncogene in diverse cancers. However, the role of miR-146a in ccRCC has not been clarified.
Cell adhesion molecule (CADM) 2, also known as SynCAM 2, IGSF4D, or Necl-3, is a newly identified protein that belongs to the CADM family and may act as a tumor suppressor [22] [23] [24] . CADM2 gene expression was high in ovarian cancer [25] , prostate cancer [26] , and lymphoma and melanoma [27, 28] . It was recently, reported that CADM2 suppressed the growth of prostate cancer cells [26] . In addition, loss of CADM2 expression promoted human renal cell carcinoma tumor progression [29] . However, the role of CADM2 in ccRCC remains unclear.
In the present study, we found that miR-146a was up-regulated in human ccRCC tissues and promoted ccRCC cell proliferation, migration, and invasion. We demonstrated that hypoxia can induce the expression of miR-146a. In addition, miR-146a targeted the 3' untranslated region (UTR) of CADM2 and down-regulated its expression. Furthermore, we demonstrated that CADM2 can inhibit the malignant phenotype in ccRCC cells. Thus, miR146a could accelerate the progression of ccRCC through the down-regulation of CADM2 expression.
Materials and Methods
Tissue specimens and cell lines ccRCC tissues and adjacent non-tumor tissues were obtained from the Tianjin Medical University General Hospital. The diagnoses of these samples were confirmed by two pathologists according to standard classifications. All procedures involving human participants were approved by the ethics committee of our institution.
786-O, A498, Caki-1, and ACHN cells were cultured and propagated in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum. Wild-type VHL-expressing 786-O WT VHL cells and VHL-deficient 786-O parental cells were grown according to previously described methods [43] . Vector construction miR-146a mimic and inhibitor, CADM2 overexpression and knockdown plasmids, and HIF2α siRNA were obtained from Invitrogen (Carlsbad, CA). The 3' UTR of CADM2 fragment or the mutant sites of the miR-146a-targeting site were inserted into pGL3-promoter reporter vector to construct 3' UTR of CADM2 and 3' UTR-MUT of CADM2 gene expression plasmids.
RNA isolation and real-time PCR
Total RNA was purified using the TRIzol (Invitrogen) method. Real-time PCR was performed as described previously. A SYBR Premix Ex Taq II kit (Takara Bio, Kusatsu, Japan) was used following the manufacturer's instructions. β-actin mRNA was used as the internal control for detecting mRNA, or U6 RNA was used as the internal control for detecting miRNA. The RT-qPCR procedure has been described in detail elsewhere [44] . The following primers were used for RT-qPCR: miR-146a sense, 5'-TGAGAACTGAATTCCATGGGT-3'; miR-146a antisense, 5'-GCAGGGTCCGA GGTATTC-3'; U6 sense, 5'-GCTTCGGCAGCACATATACTAAAAT-3'; U6 antisense, 5'-CGCTTCACGAATTTGCGTGTCAT-3'; CADM2 sense, 5'-AATCGC AAGACATTCACTG-3'; CADM2 antisense, 5'-ACAGCCACTATTCCTCC-3'; β-actin sense, 5'-GGCTGTATTCCCCTCCATCG-3'; β-actin antisense, 5'-CCAGTT GGTAACAAT GCCATGT-3'.
Western blotting
The transfected cells were lysed in RIPA lysis buffer (1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 1 mM MgCl 2 , and 10 mM Tris-HCl; pH 7.4). Rabbit antibodies against β-actin, HIF2α, VHL, E-cadherin, and vimentin were purchased from Abcam (Cambridge, UK). β-actin was used as the endogenous control to normalize the expression level of CADM2, E-cadherin, and vimentin.
MTT, colony formation, and migration and invasion assays
The MTT, colony formation, and migration and invasion assays have been described previously [45, 46] .
Immunohistochemical staining and immunofluorescence
Immunohistochemical staining was performed using anti-CADM2 antibody (1:50). The procedures used in this study have been previously described [47] . For the immunofluorescence assay, cells were incubated with anti-CADM2 antibody (1:100) and viewed using fluorescence microscopy. This assay was performed according to the method described by Zhao et al. [48] .
Fluorescent reporter assay ACHN cells were transfected with miR-146a or NC mimics together with the pLuc-CADM2-3' UTR reporter or pLuc-CADM2-3' UTR-MUT vectors in 48-well plates. pRL-TK was introduced as a transfection efficiency control. Further details have been reported previously [49] . The miR-146a promoter-luciferase reporter vector was constructed by ligating the pGL3 vector (Promega, Madison, WI) with miR-146a promoter.
Tumor xenograft model in nude mice
The ACHN cells were transfected with miR-146a or NC vector mimics. A total of 5 × 10 6 transfected cells were suspended in 0.1 mL serum-free DMEM culture medium and were subcutaneously injected into the flank of 4-to 5-week-old male nude mice according to previously described methods [49] .
ChIP assay
ChIP experiments were performed as previously described [50] . Monoclonal rabbit anti-HIF2α anti-IgG antibody was obtained from Abcam. RT-qPCR was performed in triplicate using promoter-specific primers. The following PCR primer sequences were used: primer 1 sense, 5'-TGCACA ACGTAGATGACTGTTTAGAC-3'; primer 1 antisense, 5'-GCAGCTCTGCTGAGG AAACC-3'; primer 2 sense, 5'-CCCACACCTTCCTCCTTTCTC-3'; primer 2 antisense, 5'-GCCTTAAATAGACCCCCATGCT-3'; GAPDH-sense, 5'-TGGAACAGGGAGG AGCAGAGAGCA-3'; GAPDH-antisense, 5'-TACTCGCGGCTTTACGGG-3'. 
Results

Expression of miR-146a and CADM2 in ccRCC tissues
In order to investigate the role of miR-146a and CADM2 in ccRCC, the expression levels of miR-146a and CADM2 were determined by reverse transcription quantitative PCR (RT-qPCR) in ccRCC tumor tissues (with and without VHL mutation). The results showed that miR-146a was significantly up-regulated (Fig. 1A) , while the expression of CADM2 was down-regulated in ccRCC tumor tissues (Fig. 1B ) compared with the adjacent non-tumor tissues. Moreover, Pearson's correlation analysis was performed to investigate the relationships between miR-146a, CADM2, and VHL. We found that VHL was inversely correlated with miR-146a expression in ccRCC tissues (Fig. 1C ). In addition, VHL was positively correlated with CADM2 mRNA in ccRCC tissues (Fig.  1D ). As shown in Fig. 1E , there was a negative correlation between miR-146a and CADM2 mRNA in ccRCC tissues. The association between miR146a and survival rate in ccRCC patients was analyzed. We found that ccRCC patients with a high survival rate had a low expression of miR-146a, whereas the survival rate was low when the expression of miR-146a was high (Fig. 1F) . Thus, the results demonstrated that miR-146a acts as an oncogene in ccRCC and CADM2 may serve as a tumor suppressor. In addition, the expression levels of miR-146a and CADM2 were negatively and positively related to VHL in ccRCC tissues, respectively.
Hypoxia induces expression of miR-146a
It was reported that VHLdeficient ccRCC cell lines express HIF2α [30] . Given that miR-146a expression was related to VHL in ccRCC tissues, we hypothesized that the expression of miR-146a may be affected by HIF2α. First, we compared HIF2α expression in a VHL-deficient parental 786-O cell line (786-O parental cells) 
miR-146a induces cell proliferation and invasion in ccRCC cells
To demonstrate the function of miR-146a in ccRCC cells, miR-146a expression was first measured in multiple ccRCC cell lines. Fig. 3A shows that miR-146a was relatively highly expressed in 786-O and A498 cells, while expression was relatively low in Caki-2 and ACHN cells. Next, miR-146a was overexpressed in ACHN cells and decreased in 786-O cells to examine the effect of miR-146a on proliferation and mobility of ccRCC cells. The results of methyl thiazolyl tetrazolium (MTT), cell growth, and colony formation assays showed that overexpression of miR-146a promoted ACHN cell proliferation, and decreased miR-146a expression inhibited 786-O cell proliferation compared with the corresponding control group (Fig. 3B, C, D) . In addition, the transwell assay was performed to investigate the effect of miR-146a on migration and invasion of ccRCC cells. The results showed that, compared with the control group, miR-146a mimics promoted migration and invasion in ACHN cells, and inhibitor-miR-146a suppressed migration and invasion of 786-O cells (Fig. 3E, F ). These results demonstrate that miR-146a promoted cell proliferation, migration, and invasion in ccRCC cells.
miR-146 targets CADM2
As CADM2 expression has been reported to be down-regulated in ccRCC tissues and inversely associated with the expression of miR-146a, we hypothesized that high expression levels of miR-146a may induce ccRCC malignancy by modulating CADM2 expression. Bioinfomatic tools including PicTar, TargetScan, and RNAhybrid were used to predict CADM2 as the candidate target of miR-146a. To confirm whether CADM2 is targeted by miR-146a, luciferase reporter plasmids carrying the 3' UTR of CADM2 fragment or the mutant sites of the miR-146a-targeting site were constructed (Fig. 4A) . Results from the luciferase reporter assay indicated that, compared with control group, over-expression of miR-146a reduced the CADM2 3' UTR fluorescence intensity in ACHN cells, but the fluorescence intensity of CADM2 3' UTR mutant nucleotide (MUT). was not influenced by miR-146a (Fig. 4B) . Next, western blotting and RT-qPCR were performed to examine the regulatory role of miR-146a on the endogenous protein and mRNA of CADM2 in ccRCC cells. The results showed that mRNA and protein expression of CADM2 were reduced by overexpressing miR-146a in ACHN cells or increased by inhibitor-miR-146a in 786-O cells (Fig. 4C, D) . Immunofluorescence analysis confirmed the role of miR-146a in CADM2 expression (Fig. 4E) . These data showed that miR146a targets the 3' UTR of CADM2 and negatively regulates its expression. 
CADM2 inhibits cell proliferation and invasion in ccRCC
To determine the role of CADM2 in ccRCC cell lines, we evaluated the effect of CADM2 on cellular phenotypes. We transfected with the CADM2 knockdown plasmid si-CADM2 in ACHN cells, while CADM2 overexpressed plasmid CADM2-OE in 786-O cells. Fig. 5A shows that the effectiveness of si-CADM2 in ACHN cells and of CADM2-OE in 786-O cells was verified. The MTT, cell growth, and colony formation assays showed that compared with the control group, si-CADM2 promoted cell proliferation in ACHN cells while CADM2-OE suppressed 786-O cell proliferation (Fig. 5B-D) . The results of the transwell assay showed that si-CADM2 promoted migration and invasion in ACHN cells, and CADM2-OE inhibited migration and invasion of 786-O cells compared with the corresponding control group (Fig. 5E, F) . These results showed that CADM2 inhibits the malignant phenotype of ccRCC cells.
miR-146a regulated the cell malignant phenotype and epithelial-mesenchymal transition (EMT) is mediated by CADM2
To demonstrate that the phenotype of miR-146a in ccRCC cells was mediated by repressing CADM2, we performed a series of rescue experiments. miR-146a or NC mimics were introduced to ACHN cells that had been transfected with CADM2-OE and the control vector OE-NC, respectively. Over-expression of CADM2 counteracted the promoting effect of miR-146a on cell proliferation, migration, and invasion (Fig. 6A, B) . Next, we examined CADM2 protein levels and EMT molecular markers due to miR-146a or CADM2. In ACHN cells, over-expression of miR-146a caused a reduction in protein level of CADM2 and E-cadherin while increasing the protein level of vimentin. Moreover, CADM2 over-expression increased CADM2 and E-cadherin protein levels, resulting in a decrease in vimentin protein level counteracting the effect of miR-146a on CADM2 and EMT molecular markers (Fig. 6C, D) . These results indicated that CADM2 is an important mediator of the regulation of miR-146a in ccRCC. 
miR-146a promoted tumor growth in vivo
To confirm the function of miR-146a in ccRCC tumor growth in vivo, experiments were performed using a nude mouse tumor xenograft model. As shown in Fig. 7A -C, average tumor weight and volume were lower in the miR-146a group than in the control group. As expected, tumors from the miR-146a group showed significantly lower staining intensity for CADM2 compared with tumors from the control group (Fig. 7D) . These findings indicate that miR-146a promotes tumor growth in vivo.
Discussion
It has been shown that miRNAs play an important role in regulating cellular biology, and dysregulation of miRNA expression is related to the progression of cancer [31] . Multiple miRNAs, including miR-138 [13] , miR-122 [32] , miR-101 [33] , miR-206 [34] , and miR-429 [35] , have been dysregulated and play an important role in crucial cellular biological processes in ccRCC, including cell proliferation, migration, and invasion, as well as apoptosis. In the present study, we found that miR-146a was up-regulated in ccRCC tissues compared with the adjacent non-tumor tissue. In addition, the high expression of miR-146a in ccRCC tumor tissues led us to examine the function of this miRNA. Herein, we demonstrated that miR-146a promoted cell proliferation, migration, and invasion in ccRCC.
Tumor hypoxia has been shown to be a prognostic factor for solid tumors [36] . Most ccRCCs with VHL mutations show enhanced transcriptional activity of HIF-1α, resulting in HIF activity and hypoxia gene expression [37, 38] . miRNAs also show a change in response to hypoxic conditions [39] . In this study, we found that HIF2α promoted miR-146a expression by enhancing its promoter activity. Our findings suggest that miR-146a accelerates the progression of ccRCC.
miRNA acts via down-regulation of target gene expression [40] . We used three bioinformatics tools to explore the mechanisms underlying the promotion of malignant behavior of ccRCC cells by miR-146a, and predicted the candidate target genes of miR-146a. CADM2 has been reported to be tumor suppressor gene [26] . Moreover, the high scores that bioinformatics prediction and the function of candidate target genes were considered, CADM2 was chosen as a direct target of miR-146a for further experiments. We used the luciferase reporter assay to confirm that miR-146a targeted the 3' UTR of CADM2. Moreover, miR-146a reduced the mRNA and protein levels of CADM2. There is a negative correlation between miR-146a and CADM2 mRNA levels in ccRCC tissues. Here, we showed that CADM2 suppressed cell proliferation, migration, and invasion in ccRCC cells, indicating that miR146a stimulated a malignant phenotype in ccRCC cells, at least partly by regulating CADM2. Other mechanisms by which miR-146a regulates ccRCC need to be investigated further. CADM2 is a member of the CADM family, which has been characterized to promote cell aggregation and organize the function of synapses through heterophilic adhesion [22] . In the progression of carcinogenesis, oncogenic changes facilitate cell mobility which may influence the malignant phenotype of cancer cells. The EMT, in which tumor cells lose epithelial gene expression and cell-to-cell adhesion and acquire mesenchymal characteristics, drives malignancy. In general, the most commonly used markers are E-cadherin and vimentin for the epithelial and mesenchymal traits, respectively [41, 42] . In the present study, we showed that miR-146a suppressed E-cadherin expression but increased the expression of vimentin, which suggests that miR-146a can repress the EMT to regulate migration and invasion of ccRCC cells. In addition, rescue studies demonstrated that CADM2 over-expression increased the level of E-cadherin, resulting in a decrease in vimentin protein level counteracting the effect of miR-146a on CADM2 and EMT molecular markers, indicating that miR-146a could promote the progression of EMT in ccRCC cells partly through down-regulating CADM2 expression.
In summary, our results showed that miR-146a promoted cell proliferation, migration, and invasion of ccRCC cells and hypoxia enhanced the promoter activity of miR-146 to upregulate its expression. In future studies we aim to investigate whether miR-146 transcription factors can interact with CADM2 under hypoxic conditions, thereby examining the potential mechanisms for inducing miR-146a promoter under these conditions. Moreover, miR146a down-regulated CADM2 expression through targeting the 3' UTR. CADM2 inhibited tumorigenesis of ccRCC cells and mediated the cancer promoting effect of miR-146a on ccRCC progression. These findings may provide new insights into the mechanisms of ccRCC progression and therapeutic strategies for ccRCC.
Conclusion
We have demonstrated that hypoxia induced the expression of miR-146a, which promotes a malignant phenotype in ccRCC cells. Thus, miR-146a may accelerate the progression of ccRCC through the down-regulation of CADM2 expression. 
